Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HS-20089 in recurrent or metastatic ovarian cancer and endometrial cancer
CTR20232465Phase 2Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mocertatug rezetecan in ovarian cancer, endometrial cancer (EC), sponsored by Hansoh Pharmaceutical Group. Started Jan 2024; status: active.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on CTR20232465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232465.